The FDA granted rare pediatric disease designation to iopofosine-131 for treating relapsed or refractory pediatric high-grade glioma.   Read more: https://www.curetoday.com/view/fda-grants-rare-pediatric-designation-for-iopofosine-131-in-glioma-subset

Using fruit flies, University of Wisconsin–Madison researchers have developed a new model for investigating the genetic drivers of a rare but aggressive brain tumor in children. The work has already identified potential treatment targets for the deadly cancer that has previously had few therapeutic options. Read more: https://medicalxpress.com/news/2025-10-uncover-treatment-devastating-childhood-brain.html

A new study, led by researchers at Children's Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA that are missing...

A collaborative study between Dana-Farber Cancer Institute and the Broad Institute found that 8.9% of children with glioma, the most...

Childhood brain tumor survival depends on the type of tumor. Comparing survival rates across countries is difficult, because brain tumors...

By creating a registry of tumor-infiltrating cells, researchers are hopeful that they can develop effective and personalized treatments...

After completing treatment for brain tumor, children continue to experience problems with body function. These findings were published in...

Part of a broader research study, the findings are helping to shape potential treatment approaches for patients with glioma based on the...

In order for oncology nurses to provide comprehensive support to patients and families going through pediatric brain cancer diagnosis,...

A groundbreaking study led by researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and the Broad Institute of...